ArticleBMC cancer2026
High endothelial venules abundance in tertiary lymphoid structures: a prognostic biomarker in non-small cell lung cancer with neoadjuvant immunochemotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHigh endothelial venules (HEV) in tertiary lymphoid structures (TLS) are associated with favorable prognoses in malignancies. However, regarding neoadjuvant immunochemotherapy for non-small cell lung cancer (NSCLC), HEV production and its relationship with therapeutic response are poorly elucidated. This study aims to investigate the discrepancy in HEV abundance among NSCLC patients receiving neoadjuvant therapy, as well as the value of the HEV/TLS index as an innovative prognostic marker.
methodsEighty-eight formalin-fixed paraffin-embedded (FFPE) tissues were retrospectively collected from patients with NSCLC and divided into two cohorts: neoadjuvant immunochemotherapy (N = 48) and neoadjuvant chemotherapy (N = 40). We analyzed the differences in HEV abundance score between the cohorts and their relationship with the prognosis. Kaplan–Meier method was used to explore the effect of each indicator on recurrence-free survival (RFS) and overall survival (OS). Receiver operating characteristic (ROC) curves including HEV abundance and HEV/TLS index were plotted to compare the predictive effects of different indicators by area under curve (AUC).
resultsHEV were mostly commonly found in the peripheral region (94.2%) within TLS and rarely in the geminal centers compartment (5.8%). The neoadjuvant immunochemotherapy cohort had higher levels of major pathological response (MPR) rate and pathological complete response (pCR) rate than neoadjuvant chemotherapy cohort (MPR: 29.1% vs. 15.0%; pCR: 29.1% vs. 5.0%). Furthermore, neoadjuvant immunochemotherapy exhibited higher HEV abundance score (p < 0.001) and significantly better prognostic RFS (p = 0.0321) and OS (p = 0.0319). Multivariate analysis demonstrated that HEV abundance score remains the most prominent immunological prognostic factor affecting RFS (hazard ratio [HR] = 0.113) and OS (HR = 0.009) after adjusting variables. We found that the predictive accuracy of the combined HEV/TLS index was superior to that of HEV abundance score alone.
conclusionThe HEV/TLS index was more effective than HEV abundance score in predicting patients’ prognosis. Therefore, the induction of HEV formation within TLS to increase their abundance may be a potential strategy to enhance the efficacy of neoadjuvant immunochemotherapy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.